In one way the shareholder update tells us remarkably little which may indicate that what it does tell us is remarkably significant. Reference the upcoming reports on final validation studies for MYC hits and repeat experiments on CPP Omomyc fusion.
Given that there is not a lot to say except to expect a report on studies in early Q4 2015, does tend to highlight the importance of those very same reports. Would you build expectations if the results were not (or substantially) already known or at least experiments were going swimmingly? Its not as if the studies are double blind, placebo controlled randomised clinical trials. The fact that the results are due early this quarter which to all intents and purposes could be tomorrow or the next day, may give it away.
Speaking of clinical trials we have a process to take a lead candidate forward. Again, the notification of a series of reviews with an externally facilitated process tends to highlight the success of current endeavours in relation to MYC hits/CPP Omomyc fusion.
That at least is the glass half full interpretation.
PYC Price at posting:
1.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)